Literature DB >> 25379953

Deficiency of the tumor promoter gene wip1 induces insulin resistance.

Heather L Armata1, Sally Chamberland, Lauren Watts, Hwi Jin Ko, Yongjin Lee, Dae Young Jung, Jason K Kim, Hayla K Sluss.   

Abstract

Diabetes is a growing health care issue, and prediabetes has been established as a risk factor for type 2 diabetes. Prediabetes is characterized by deregulated glucose control, and elucidating pathways which govern this process is critical. We have identified the wild-type (WT) p53-inducible phosphatase (WIP1) phosphatase as a regulator of glucose homeostasis. Initial characterization of insulin signaling in WIP1 knockout (WIP1(KO)) murine embryo fibroblasts demonstrated reduced insulin-mediated Ak mouse transforming activation. In order to assess the role of WIP1 in glucose homeostasis, we performed metabolic analysis on mice on a low-fat chow diet (LFD) and high fat diet (HFD). We observed increased expression of proinflammatory cytokines in WIP1(KO) murine embryo fibroblasts, and WIP1(KO) mice fed a LFD and a HFD. WIP1(KO) mice exhibited glucose intolerance and insulin intolerance on a LFD and HFD. However, the effects of WIP1 deficiency cause different metabolic defects in mice on a LFD and a HFD. WIP1(KO) mice on a LFD develop hepatic insulin resistance, whereas this is not observed in HFD-fed mice. Mouse body weights and food consumption increase slightly over time in LFD-fed WT and WIP1(KO) mice. Leptin levels are increased in LFD-fed WIP1(KO) mice, compared with WT. In contrast, HFD-fed WIP1(KO) mice are resistant to HFD-induced obesity, have decreased levels of food consumption, and decreased leptin levels compared with HFD-WT mice. WIP1 has been shown to regulate the nuclear factor kappa-light-chain-enhancer of activated B cells pathway, loss of which leads to increased inflammation. We propose that this increased inflammation triggers insulin resistance in WIP1(KO) mice on LFD and HFD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25379953      PMCID: PMC4280527          DOI: 10.1210/me.2014-1136

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  34 in total

Review 1.  The many substrates and functions of ATM.

Authors:  M B Kastan; D S Lim
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

2.  Wip1 phosphatase modulates ATM-dependent signaling pathways.

Authors:  Sathyavageeswaran Shreeram; Oleg N Demidov; Weng Kee Hee; Hiroshi Yamaguchi; Nobuyuki Onishi; Calvina Kek; Oleg N Timofeev; Crissy Dudgeon; Albert J Fornace; Carl W Anderson; Yasuhiro Minami; Ettore Appella; Dmitry V Bulavin
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

3.  Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart.

Authors:  Alfonso Mora; Kei Sakamoto; Edward J McManus; Dario R Alessi
Journal:  FEBS Lett       Date:  2005-07-04       Impact factor: 4.124

4.  The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.

Authors:  Xiongbin Lu; Ou Ma; Thuy-Ai Nguyen; Stephen N Jones; Moshe Oren; Lawrence A Donehower
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

5.  PPM1D is a potential target for 17q gain in neuroblastoma.

Authors:  Fumiko Saito-Ohara; Issei Imoto; Jun Inoue; Hajime Hosoi; Akira Nakagawara; Tohru Sugimoto; Johji Inazawa
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

6.  Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation.

Authors:  Marco L Schito; Oleg N Demidov; Shin'ichi Saito; Jonathan D Ashwell; Ettore Appella
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors.

Authors:  R S Bar; W R Levis; M M Rechler; L C Harrison; C Siebert; J Podskalny; J Roth; M Muggeo
Journal:  N Engl J Med       Date:  1978-05-25       Impact factor: 91.245

8.  Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo.

Authors:  Hyo-Jeong Kim; Takamasa Higashimori; So-Young Park; Hyejeong Choi; Jianying Dong; Yoon-Jung Kim; Hye-Lim Noh; You-Ree Cho; Gary Cline; Young-Bum Kim; Jason K Kim
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

9.  The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.

Authors:  Hiroshi Yamaguchi; Stewart R Durell; Deb K Chatterjee; Carl W Anderson; Ettore Appella
Journal:  Biochemistry       Date:  2007-10-16       Impact factor: 3.162

10.  Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis.

Authors:  Heather L Armata; Diane Golebiowski; Dae Young Jung; Hwi Jin Ko; Jason K Kim; Hayla K Sluss
Journal:  Mol Cell Biol       Date:  2010-10-18       Impact factor: 4.272

View more
  3 in total

1.  WIP1 phosphatase is a critical regulator of adipogenesis through dephosphorylating PPARγ serine 112.

Authors:  Dahu Li; Lijun Zhang; Lun Xu; Lili Liu; Yunling He; Yiyao Zhang; Xin Huang; Tong Zhao; Liying Wu; Yongqi Zhao; Kuiwu Wu; Hui Li; Xiao Yu; Taiyun Zhao; Shenghui Gong; Ming Fan; Lingling Zhu
Journal:  Cell Mol Life Sci       Date:  2017-02-08       Impact factor: 9.261

2.  Wild-type p53-induced Phosphatase 1 Deficiency Exacerbates Myocardial Infarction-induced Ischemic Injury.

Authors:  Ke-Mei Liu; Hai-Hong Zhang; Ya-Nan Wang; Lian-Mei Wang; Hong-Yu Chen; Cai-Feng Long; Lian-Feng Zhang; Hong-Bing Zhang; Hong-Bing Yan
Journal:  Chin Med J (Engl)       Date:  2017-06-05       Impact factor: 2.628

3.  Inhibition of lipid droplet formation by Ser/Thr protein phosphatase PPM1D inhibitor, SL-176.

Authors:  Rui Kamada; Nozomi Kimura; Fumihiko Yoshimura; Keiji Tanino; Kazuyasu Sakaguchi
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.